Will Ratings have more impact than Precision Medicine approaches to Clinical Trials?


This interesting JAMA article suggests that a Precision Medicine Approach to Clinical Trials  is an evolutionary not revolutionary step.

I agree. Clearly Patients are desperate to be involved in this industry but in just a few years it’s going to seem such an outdated idea to make an appointment with a specific clinic in the hope of finding a Physician who will be able to match you with a clinical trial that will accept you.

“Five or 6 years ago, only 5% to 10% of patients at David Hong, MD,’s clinic arrived with a mutational profile of their tumor. Today, it’s more like 25% to 30%. They come bearing their tumor profile in the hope that they’ll qualify for one of a growing number of clinical trials targeting specific biomarkers, a strategy called precision medicine. Desperate, some come already knowing that they qualify for a particular trial, thanks to Facebook groups for cancer patients whose tumors share the same genetic abnormality and other online resources”

As I explain in this talk I gave at the Mobile Clinical Congress in Edinburgh the step change happens when we think like the BornMobile generation and let Patients and Clinicians rate Clinical Trials


About David Doherty

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s